Neoadjuvant chemotherapy (NAC) and complementary radiotherapy can also minimize the use of ALND; however, only a small proportion of patients with triple-negative (TNBC) or HER2+ breast cancer (tumor >2 cm), or those who have opted for breast-conserving surgery but are contraindicated due to their tumor-to-breast volume ratio, are offered NAC (9). The gene discussed is ERBB2; the disease is breast cancer.